An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ANN ARBOR, Mich.--(BUSINESS WIRE)--
ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months ended March 31, 2023 on Monday, May 15, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.
Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing (844) 868-8846 (U.S.) or (412) 317-5465 (International). A webcast of the call can also be accessed at ENDRA’s Investor Relations page and here.
A telephone replay will be available until May 22, 2023 by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and providing the passcode 8983905. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with the more than 700,000 ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
endra life sciences is bringing new capabilities to ultrasound. our photo-acoustic solutions help medical researchers screen and modify disease models with unparalleled quality and speed. we’re proud to have a global installed base of leading institutions using our nexus-128 system, the only 3d imaging solution for imaging anatomy, physiology and labeled molecular targets. the nexus 128 is a preclinical photoacoustic computed tomography (ct) scanner for small animal imaging. the system is used for simple, fast, non-invasive quantification of physiological parameters such as tumor vasculature without ionizing radiation. the fully-3d imaging technology used by the nexus 128 provides increased sensitivity compared to slice-based scanners, and dynamic (4-d) photoacoustic ct scans allow for applications such as quantification of probe uptake. the nexus 128 is currently being used by top imaging laboratories around the globe.